

Eliseo Pascual

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3859133/publications.pdf>

Version: 2024-02-01

88
papers

6,741
citations

147801

31
h-index

64796

79
g-index

95
all docs

95
docs citations

95
times ranked

4459
citing authors

#	ARTICLE	IF	CITATIONS
1	Identifying Potential Classification Criteria for Calcium Pyrophosphate Deposition Disease: Item Generation and Item Reduction. <i>Arthritis Care and Research</i> , 2022, 74, 1649-1658.	3.4	23
2	A small dose of intraarticular triamcinolone plus mepivacaine provides a rapid and sustained relief for gout flares. <i>Reumatologia Clínica</i> , 2022, 18, 129-130.	0.5	0
3	A small dose of intraarticular triamcinolone plus mepivacaine provides a rapid and sustained relief for gout flares. <i>Reumatologia Clínica (English Edition)</i> , 2022, 18, 129-130.	0.3	0
4	Birefringent crystals deposition and inflammasome expression in human atheroma plaques by levels of uricemia. <i>Joint Bone Spine</i> , 2022, 89, 105423.	1.6	3
5	Acute arthritis following SARS-CoV-2 infection. <i>Journal of Medical Virology</i> , 2021, 93, 661-661.	5.0	9
6	Reviewing Disease Activity Indices in Spondyloarthritis From the Sex Perspective: A Systematic Review and Metaanalysis. <i>Journal of Rheumatology</i> , 2021, 48, 1395-1404.	2.0	7
7	2018 updated European League Against Rheumatism evidence-based recommendations for the diagnosis of gout. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 31-38.	0.9	225
8	Progresses in the imaging of calcium pyrophosphate crystal disease. <i>Current Opinion in Rheumatology</i> , 2020, 32, 140-145.	4.3	5
9	Mixed Crystal Disease: A Tale of 2 Crystals. <i>Journal of Rheumatology</i> , 2020, 47, 1158-1159.	2.0	4
10	Gout. <i>Journal of Clinical Rheumatology</i> , 2020, 26, 208-212.	0.9	0
11	Is Remission a Valid Target for Gout?. <i>Journal of Rheumatology</i> , 2020, 47, 4-5.	2.0	3
12	Gout, Hyperuricemia, and Crystal-Associated Disease Network Consensus Statement Regarding Labels and Definitions for Disease Elements in Gout. <i>Arthritis Care and Research</i> , 2019, 71, 427-434.	3.4	73
13	Gout, Hyperuricaemia and Crystal-Associated Disease Network (G-CAN) consensus statement regarding labels and definitions of disease states of gout. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 1592-1600.	0.9	72
14	Most needle-shaped calcium pyrophosphate crystals lack birefringence. <i>Rheumatology</i> , 2019, 58, 1095-1098.	1.9	12
15	Synovial fluid leukocyte count in asymptomatic hyperuricaemia with crystal deposition: a proof-of-concept study. <i>Rheumatology</i> , 2019, 58, 1104-1105.	1.9	7
16	Crystal Analysis in Synovial Fluid. , 2019, , 47-58.		0
17	Therapy for CPPD: Options and Evidence. <i>Current Rheumatology Reports</i> , 2018, 20, 31.	4.7	24
18	Impaired Trunk Posture in Women With Fibromyalgia. <i>Spine</i> , 2018, 43, 1536-1542.	2.0	7

#	ARTICLE	IF	CITATIONS
19	Managing Gout in the Patient with Renal Impairment. <i>Drugs and Aging</i> , 2018, 35, 263-273.	2.7	10
20	Joint nociceptor nerve activity and pain in an animal model of acute gout and its modulation by intra-articular hyaluronan. <i>Pain</i> , 2018, 159, 739-748.	4.2	18
21	SUA levels should not be maintained ≤ 3 mg/dL for several years. Response to â€ˆEULAR gout treatment guidelines by Richette <i>et al</i>: uric acid and neurocognition by Singh <i>et al</i>â€™. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, e21-e21.	0.9	2
22	Interleukin-6 pathway blockade as an option for managing refractory cases of crystal arthritis: Two cases report. <i>Joint Bone Spine</i> , 2018, 85, 377-378.	1.6	9
23	Challenges to conquer from the gender perspective in medicine: The case of spondyloarthritis. <i>PLoS ONE</i> , 2018, 13, e0205751.	2.5	20
24	Urate crystals and inflammation. Cardiovascular impact of gout. <i>International Journal of Cardiology</i> , 2018, 271, 295.	1.7	0
25	Cardiovascular risk of patients with gout seen at rheumatology clinics following a structured assessment. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 1263-1268.	0.9	38
26	Clinical Images: Hematoidin in Synovial Fluid. <i>Arthritis and Rheumatology</i> , 2017, 69, 836-836.	5.6	1
27	Response: Renal dosing of allopurinol results in suboptimal gout care by T Neogi <i>et al</i>. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, e2-e2.	0.9	7
28	Inflammatory status and uricaemia determine HDL-cholesterol levels in hypertensive adults over 65: an analysis of the FAPRES register. <i>Rheumatology International</i> , 2017, 37, 941-948.	3.0	1
29	Severe gout: Strategies and innovations for effective management. <i>Joint Bone Spine</i> , 2017, 84, 541-546.	1.6	18
30	2016 updated EULAR evidence-based recommendations for the management of gout. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 29-42.	0.9	1,096
31	Understanding How the Diagnostic Delay of Spondyloarthritis Differs Between Women and Men: A Systematic Review and Metaanalysis. <i>Journal of Rheumatology</i> , 2017, 44, 174-183.	2.0	85
32	Sex and Gender Interactions in the Lives of Patients with Spondyloarthritis in Spain: A Quantitative-qualitative Study. <i>Journal of Rheumatology</i> , 2017, 44, 1429-1435.	2.0	6
33	Current advances in therapies for calcium pyrophosphate crystal arthritis. <i>Current Opinion in Rheumatology</i> , 2016, 28, 140-144.	4.3	8
34	Silent Monosodium Urate Crystal Deposits Are Associated With Severe Coronary Calcification in Asymptomatic Hyperuricemia: An Exploratory Study. <i>Arthritis and Rheumatology</i> , 2016, 68, 1531-1539.	5.6	74
35	Febuxostat for Patients With Gout and Severe Chronic Kidney Disease: Which Is the Appropriate Dosage? Comment on the Article by Saag et al. <i>Arthritis and Rheumatology</i> , 2016, 68, 2563-2564.	5.6	9
36	Editorial: Decreasing Crystalâ€™induced Consternation: New Methods of Crystal Identification. <i>Arthritis and Rheumatology</i> , 2016, 68, 1574-1577.	5.6	4

#	ARTICLE	IF	CITATIONS
37	Gout mimicking rheumatoid arthritis. <i>Seminars in Arthritis and Rheumatism</i> , 2016, 45, e28.	3.4	1
38	Gout: optimizing treatment to achieve a disease cure. <i>Therapeutic Advances in Chronic Disease</i> , 2016, 7, 135-144.	2.5	27
39	Gout and the heart: beyond comorbidities. <i>International Journal of Clinical Rheumatology</i> , 2015, 10, 329-334.	0.3	0
40	An Unusual Tophus. <i>New England Journal of Medicine</i> , 2015, 372, e6.	27.0	6
41	Methotrexate: should it still be considered for chronic calcium pyrophosphate crystal disease?. <i>Arthritis Research and Therapy</i> , 2015, 17, 89.	3.5	6
42	Comment on: The validation of a diagnostic rule for gout without joint fluid analysis: a prospective study. <i>Rheumatology</i> , 2015, 54, 1328-1329.	1.9	2
43	Mechanisms of crystal formation in gout—a structural approach. <i>Nature Reviews Rheumatology</i> , 2015, 11, 725-730.	8.0	79
44	Effects of Xanthine Oxidase Inhibitors on Cardiovascular Disease in Patients with Gout: Ascertaining the Efficacy of Treatment Matters. <i>American Journal of Medicine</i> , 2015, 128, e41-e42.	1.5	1
45	Rapid crystal dissolution in gout: is it feasible and advisable?. <i>International Journal of Clinical Rheumatology</i> , 2014, 9, 395-401.	0.3	2
46	Ultrasound-detected musculoskeletal urate crystal deposition: which joints and what findings should be assessed for diagnosing gout?. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 1522-1528.	0.9	155
47	Improving cardiovascular and renal outcomes in gout: what should we target?. <i>Nature Reviews Rheumatology</i> , 2014, 10, 654-661.	8.0	169
48	Gout: The mechanism of urate crystal nucleation and growth. A hypothesis based in facts. <i>Joint Bone Spine</i> , 2013, 80, 1-4.	1.6	27
49	Anakinra for a refractory case of intermittent hydrarthrosis with a TRAPS-related gene mutation. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 155-155.	0.9	14
50	Criteria for Gout Diagnosis?. <i>Journal of Rheumatology</i> , 2013, 40, 356-358.	2.0	12
51	Back Pain Due to Lumbar Gouty Flare — A Prospective Diagnosis. <i>Journal of Rheumatology</i> , 2013, 40, 1459-1460.	2.0	2
52	Gout treatment: should we aim for rapid crystal dissolution?. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 635-637.	0.9	22
53	Gout: why is this curable disease so seldom cured?. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, 1765-1770.	0.9	228
54	Methotrexate Is an Option for Patients With Refractory Calcium Pyrophosphate Crystal Arthritis. <i>Journal of Clinical Rheumatology</i> , 2012, 18, 234-236.	0.9	24

#	ARTICLE	IF	CITATIONS
55	Synovial Fluid Crystal Analysis. , 2012, , 20-34.		1
56	EULAR recommendations for calcium pyrophosphate deposition. Part II: Management. Annals of the Rheumatic Diseases, 2011, 70, 571-575.	0.9	193
57	European League Against Rheumatism recommendations for calcium pyrophosphate deposition. Part I: terminology and diagnosis. Annals of the Rheumatic Diseases, 2011, 70, 563-570.	0.9	418
58	Calcium pyrophosphate crystal deposition. International Journal of Clinical Rheumatology, 2011, 6, 677-688.	0.3	3
59	An Audit of the Variability of Diagnosis and Management of Gout in the Rheumatology Setting. Journal of Clinical Rheumatology, 2011, 17, 349-355.	0.9	41
60	Synovial fluid analysis for crystals. Current Opinion in Rheumatology, 2011, 23, 161-169.	4.3	62
61	International position paper on febuxostat. Clinical Rheumatology, 2010, 29, 835.	2.2	3
62	Febuxostat. Nature Reviews Drug Discovery, 2009, 8, 191-192.	46.4	36
63	Gout: new advances in the diagnosis and management of an old disease. International Journal of Clinical Rheumatology, 2009, 4, 203-220.	0.3	8
64	Normal Initial Magnetic Resonance Imaging in Aseptic Bone Necrosis of the Knee. Journal of Clinical Rheumatology, 2008, 14, 101-104.	0.9	5
65	Why is gout so poorly managed?. Annals of the Rheumatic Diseases, 2007, 66, 1269-1270.	0.9	72
66	Therapeutic advances in gout. Current Opinion in Rheumatology, 2007, 19, 122-127.	4.3	34
67	Time required for disappearance of urate crystals from synovial fluid after successful hypouricaemic treatment relates to the duration of gout. Annals of the Rheumatic Diseases, 2007, 66, 1056-1058.	0.9	135
68	Artrocentesis de la primera articulaci3n metatarsal5ngica. Seminarios De La Fundaci3n Espa5ola De Reumatolog5a, 2007, 8, 127-129.	0.1	0
69	EULAR evidence based recommendations for gout. Part II: Management. Report of a task force of the EULAR Standing Committee For International Clinical Studies Including Therapeutics (ESCISIT). Annals of the Rheumatic Diseases, 2006, 65, 1312-1324.	0.9	1,079
70	Acute Hip Monoarthritis in a Patient Treated With Isotretinoin. Journal of Clinical Rheumatology, 2006, 12, 105-106.	0.9	13
71	Manifestations articulaires de l'Artrite Microbienne. Revue Du Rhumatisme (Edition Francaise), 2006, 73, 362-368.	0.0	7
72	Crystal Clear? Sonographic Assessment of Gout and Calcium Pyrophosphate Deposition Disease. Seminars in Arthritis and Rheumatism, 2006, 36, 197-202.	3.4	202

#	ARTICLE	IF	CITATIONS
73	Synovial fluid analysis. Best Practice and Research in Clinical Rheumatology, 2005, 19, 371-386.	3.3	89
74	Effectiveness of recommendations to prevent reactivation of latent tuberculosis infection in patients treated with tumor necrosis factor antagonists. Arthritis and Rheumatism, 2005, 52, 1766-1772.	6.7	612
75	Analysis for crystals in synovial fluid: training of the analysts results in high consistency. Annals of the Rheumatic Diseases, 2005, 64, 612-615.	0.9	106
76	Gout. Current Opinion in Rheumatology, 2004, 16, 282-286.	4.3	24
77	Diagnosis of Intercritical Gout. Annals of Internal Medicine, 2000, 132, 843.	3.9	0
78	Gout update: from lab to the clinic and back. Current Opinion in Rheumatology, 2000, 12, 213-218.	4.3	17
79	Most calcium pyrophosphate crystals appear as non-birefringent. Annals of the Rheumatic Diseases, 1999, 58, 582-584.	0.9	94
80	Infectious Arthritis of a Lumbar Facet Joint. Journal of Clinical Rheumatology, 1999, 5, 22-24.	0.9	2
81	Synovial Fluid Analysis for Diagnosis of Intercritical Gout. Annals of Internal Medicine, 1999, 131, 756-759.	3.9	200
82	SAPHO Presenting with a Lesion in the Symphysis Pubis. Journal of Clinical Rheumatology, 1998, 4, 28-31.	0.9	0
83	Hyperuricemia and gout. Current Opinion in Rheumatology, 1994, 6, 454.	4.3	18
84	Persistence of monosodium urate crystals and low-grade inflammation in the synovial fluid of patients with untreated gout. Arthritis and Rheumatism, 1991, 34, 141-145.	6.7	172
85	Synovial Fat Necrosis Associated with Ischemic Pancreatic Disease. Arthritis and Rheumatism, 1979, 22, 547-553.	6.7	41
86	Suppressor T-cell abnormality in idiopathic systemic lupus erythematosus. Clinical Immunology and Immunopathology, 1976, 6, 192-199.	2.0	303
87	Mononuclear cells in human synovial fluid. Identification of lymphoblasts in rheumatoid arthritis. Arthritis and Rheumatism, 1976, 19, 743-748.	6.7	47
88	Acute gouty arthritis without urate crystals identified on initial examination of synovial fluid. Arthritis and Rheumatism, 1975, 18, 603-612.	6.7	43